Showing results (241-250 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
The Lancet. Haematology|January 25, 2020
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trialShinya Kimura, Jun Imagawa, Kazunori Murai, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology|May 30, 2025
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitorsAntonio M Risitano, Austin G Kulasekararaj, Phillip Scheinberg, et al.
The Lancet. Haematology|October 8, 2025
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trialLina Jin, Sinan Gu, Qianqi Ruan, et al.
The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.
The Lancet. Haematology|July 20, 2025
Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over timeKristina Kirschner, Yael Kusne, Catherine Cargo, et al.
The Lancet. Haematology|June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 studyShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
The Lancet. Haematology|April 2, 2025
Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic reviewCharles J Milrod, Lila Rubin, Boris Martinez, et al.
Pageof 73